Healthcare IoT Is Growing at 32.5% — But Can AI Find Your Medical Device Brand?

\n\n\nA cardiologist in Boston told me she uses Claude to research remote patient monitoring devices for her heart failure patients. Not as her only source — she reads clinical papers and consults colleagues too — but AI is her starting point for discovering what's available.\n\n"I'll ask something like 'What are the best FDA-cleared continuous blood pressure monitors for heart failure patients?' and use the answer to narrow my research," she explained. "If a device doesn't show up, I probably won't hear about it unless a sales rep catches me between patients."\n\nThat scenario is playing out across healthcare at an accelerating pace. The healthcare IoT market is the fastest-growing IoT segment, projected at a 32.5% CAGR with over 540 million connected medical devices worldwide. Telehealth adoption has plateaued post-pandemic but stabilized at 38% of outpatient visits — a 3,800% increase from pre-COVID levels. And the people making decisions about which devices to adopt are increasingly turning to AI for initial research.\n\nThe stakes here are different from any other IoT vertical. In smart home, AI invisibility costs you a sale. In healthcare IoT, AI invisibility could mean a superior device never reaches the patients who need it.\n\n## Three Audiences, Three Research Patterns\n\nHealthcare IoT has a uniquely fragmented buyer landscape. Unlike consumer IoT (one buyer) or industrial IoT (one buying committee), healthcare IoT serves three distinct audiences that all use AI differently but collectively determine which brands succeed.\n\nAudience 1: Hospital Procurement Teams\n\nThese are the enterprise buyers. They're evaluating remote patient monitoring (RPM) platforms, connected infusion pumps, smart bed systems, and hospital-wide IoT infrastructure. The procurement process looks a lot like industrial IoT — committees, RFPs, long sales cycles.\n\nHow they use AI: "Compare remote patient monitoring platforms for a 200-bed community hospital" or "What RPM vendors have the strongest Epic EHR integration?"\n\nWe ran 40 hospital procurement queries across all four AI engines. The most-recommended brands were:\n\n- Medtronic Care Management Services — appeared in 72% of responses\n- Philips Connected Care — appeared in 65% of responses\n- Masimo — appeared in 48% of responses\n- Biobeat — appeared in 28% of responses\n- Current Health (Best Buy Health) — appeared in 24% of responses\n\nThe pattern was clear: brands with extensive clinical evidence and EHR integration documentation dominated. Smaller RPM platforms with strong products but limited clinical publications were largely invisible.\n\nAudience 2: Physicians and Clinical Staff\n\nDoctors, nurses, and clinical specialists research devices for specific patient populations. They're not making purchasing decisions directly, but their recommendations carry enormous weight with procurement.\n\nHow they use AI: "Best continuous glucose monitors for Type 1 diabetes management" or "What wearable devices can detect atrial fibrillation?"\n\nThis is where the FDA distinction becomes critical. We found that AI engines consistently differentiate between FDA-cleared and non-cleared devices — but not always accurately. In 15% of our test queries, an AI engine either failed to mention FDA status for a cleared device or incorrectly implied clearance for a non-cleared one.\n\nThe top brands in physician queries:\n\n- Dexcom — dominated diabetes device queries with a 78% appearance rate\n- Abbott (FreeStyle Libre) — appeared in 71% of glucose monitoring queries\n- Withings — appeared in 44% of general health monitoring queries\n- Apple Watch — appeared in 62% of AFib detection queries (despite being a consumer device)\n- Medtronic — appeared in 58% of cardiac device queries\n\nAudience 3: Patients and Caregivers\n\nPatients researching their own health monitoring options represent a growing and underserved audience. They're asking questions that blend medical need with consumer practicality.\n\nHow they use AI: "I have prediabetes. What's the best glucose monitor I can buy without a prescription?" or "My mom has COPD. What home monitoring devices should we get?"\n\nPatient queries produced the most concerning results in our study. AI responses frequently mixed medical-grade devices with consumer wellness products without clearly distinguishing between them. A patient asking about blood pressure monitoring might get Withings BPM Connect (FDA-cleared) recommended alongside a $30 Amazon wrist cuff with no clinical validation, with no indication that these products serve fundamentally different purposes.\n\n## The FDA Factor: How AI Handles Regulatory Status\n\nThis is the single most important distinction in healthcare IoT AI visibility, and AI handles it inconsistently.\n\nWe tested 60 queries specifically about FDA-cleared devices. Here's what we found:\n\n- ChatGPT mentioned FDA status in 68% of responses. When it mentioned it, the information was accurate 91% of the time.\n- Claude mentioned FDA status in 82% of responses and was accurate 95% of the time. Claude was the most consistently careful about regulatory disclaimers.\n- Gemini mentioned FDA status in 55% of responses. Accuracy was 87%.\n- Perplexity mentioned FDA status in 73% of responses, often linking to FDA databases. Accuracy was 93%.\n\nNone of these rates are acceptable for healthcare. An AI engine that fails to mention FDA clearance 32-45% of the time is creating a significant information gap for patients and providers.\n\nFor device manufacturers, the implication is stark: you need to make your regulatory status so prominent and well-documented that AI engines cannot miss it. FDA clearance letters, 510(k) summaries, clinical trial results — all of this needs to be publicly accessible in structured, parseable formats.\n\n## Dexcom: A Case Study in Healthcare AI Visibility\n\nDexcom's AI visibility is worth studying because they've done almost everything right, mostly as a byproduct of good marketing rather than a deliberate AI strategy.\n\nWhy Dexcom dominates continuous glucose monitoring queries:\n\n1. Unambiguous positioning. Dexcom makes continuous glucose monitors. That's it. When AI encounters a diabetes management query, Dexcom's positioning makes the recommendation decision trivial.\n\n2. Massive clinical evidence base. Over 40 peer-reviewed studies, published outcomes data, and clinical guidelines from the American Diabetes Association that specifically mention Dexcom devices. AI engines treat clinical guidelines as high-authority sources.\n\n3. Patient community presence. Dexcom has cultivated enormous patient communities on Reddit, Facebook, and diabetes-specific forums. These communities generate thousands of authentic discussions, comparisons, and experience reports that AI engines learn from.\n\n4. Clear FDA documentation. Dexcom's FDA clearances are well-documented and easily findable. AI engines can confidently state regulatory status.\n\n5. Insurance coverage information. Dexcom publishes detailed insurance coverage guides. This matters because patient queries often include cost considerations, and AI engines that can address insurance coverage give more complete answers.\n\nCompare this to a hypothetical competitor with an equally good CGM but lacking in published clinical trials, patient community engagement, or accessible FDA documentation. The competitor's device might be equivalent in clinical performance, but if AI doesn't know about it, endocrinologists who use AI for research won't know about it either.\n\n## The Telehealth Multiplier\n\nTelehealth's stabilization at 38% of outpatient visits has created a permanent new channel for healthcare IoT recommendations. In a telehealth visit, the physician can't hand the patient a brochure or point to a device on a shelf. They have to describe it, and increasingly, patients go to AI to follow up.\n\nWe tracked the flow: physician recommends "a continuous glucose monitor" in a telehealth visit. Patient asks ChatGPT "best continuous glucose monitor for Type 2 diabetes." ChatGPT recommends Dexcom G7 and Abbott FreeStyle Libre 3. Patient orders one based on the AI recommendation, not necessarily the one the physician had in mind.\n\nThis creates a secondary influence pathway: even if a physician recommends your device by name, the patient may end up with a different brand because of what AI suggests when they go to purchase it. AI isn't just influencing the initial recommendation — it's mediating the entire decision chain.\n\n

Clinical Decision Support and AI Convergence\n\nThere's a deeper trend here that most medical device companies haven't grasped yet. AI is converging with clinical decision support systems (CDSS). Today, a doctor asks ChatGPT informally. Within two years, AI-powered CDSS tools will be embedded directly in EHR workflows, suggesting devices and treatments based on patient data.\n\nWhen that happens, device visibility in AI models won't just be a marketing concern — it will be a clinical integration requirement. If the AI-powered CDSS recommends monitoring devices and your device isn't in its knowledge base, you're excluded from the clinical workflow entirely.\n\nThe medical device companies building for this future are:\n\n- Ensuring their device data is in structured formats (FHIR, HL7) that AI systems can ingest\n- Publishing comprehensive clinical evidence in open-access journals (not paywalled)\n- Documenting integration capabilities with major EHR platforms (Epic, Cerner, Meditech)\n- Building relationships with AI companies developing healthcare-specific models\n\n## Building an AI Visibility Strategy for Healthcare IoT\n\nThe healthcare IoT GEO playbook differs from consumer and industrial IoT because of the regulatory dimension and the clinical evidence requirements. Here's the framework:\n\nFoundation: Regulatory documentation\n\nMake your FDA clearances, CE markings, clinical trial data, and intended use statements publicly accessible and clearly structured. Don't bury them in PDFs behind login walls. AI engines need to crawl this information. Put your 510(k) summary on your website. Create a dedicated regulatory information page.\n\nLayer 1: Clinical evidence\n\nPeer-reviewed publications, clinical outcomes data, guideline references. If your device is mentioned in ADA, AHA, or other professional society guidelines, make sure that connection is prominent on your website. AI engines heavily weight clinical authority sources.\n\nLayer 2: Use-case documentation\n\nFor each clinical use case your device serves, create detailed content: patient population, clinical workflow, outcomes data, insurance coverage, and comparison with alternative approaches. This content directly maps to how physicians and procurement teams query AI.\n\nLayer 3: Patient-accessible information\n\nWritten for a general audience: how the device works, what to expect, insurance coverage, setup guides, troubleshooting. This addresses the patient research queries that are growing fastest.\n\nLayer 4: Integration and interoperability\n\nEHR integration documentation, data export formats, platform compatibility. This addresses the technical evaluation queries from hospital IT teams.\n\n## The Patient Safety Dimension\n\nI want to address something that makes healthcare IoT AI visibility different from every other industry: the consequences of getting it wrong.\n\nIf AI doesn't know about your smart thermostat, you lose a sale. If AI doesn't know about your medical device, a patient might not receive optimal care.\n\nConsider this scenario: a patient with treatment-resistant hypertension asks AI about continuous blood pressure monitoring options. AI recommends Withings BPM Connect and Omron HeartGuide. But there's a clinically superior device — Biobeat's disposable continuous BP monitor — that's FDA-cleared for clinical use and has published outcomes data showing superior accuracy. AI doesn't mention it because Biobeat's online presence is limited compared to consumer-facing brands.\n\nThe patient gets a consumer device when they might have benefited from a clinical-grade one. The physician doesn't know Biobeat exists because AI didn't surface it during their research. This isn't a hypothetical — it's the kind of gap we found repeatedly in our testing.\n\nMedical device companies have a unique obligation to ensure AI can find and accurately represent their products. Not just for market share, but because information gaps in healthcare have human consequences.\n\n## Where to Start\n\nIf you're a healthcare IoT company, run a simple audit. Ask each of the four major AI engines:\n\n1. "What are the best [your device category] devices?"\n2. "Is [your brand] FDA-cleared for [your indication]?"\n3. "Compare [your brand] vs [top competitor]"\n4. "What [device category] does [professional society] recommend?"\n\nIf AI can't answer these accurately, your clinical evidence and regulatory documentation aren't reaching the models. A baseline check at geobuddy.co/check will show you how each engine currently sees your brand.\n\nThe healthcare IoT market will add 200 million connected devices in the next three years. The physicians, procurement teams, and patients choosing those devices are already asking AI for guidance. Whether AI knows about your device isn't just a marketing question anymore.\n\nIt's a patient care question. And it deserves to be treated like one.\n